Screening your patients for inherited breast and ovarian cancer: How to collect family history data

Contemporary Ob-Gyn

Volumn 43, Issue 11, 1998, Pages 107-132

  Huelsman, Karen M ^a   Huppert, Jill ^b   Fiorica, James ^c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0011145989     PISSN: 00903159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bremond A. Inherited breast and ovarian cancer: the role of the gynecologist. Eur J Obstet Gynecol Reprod Biol. 1997;75(1):95-96.
2. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Lancet. 1994;343:692-695.
3. Berchuck A, Cirisano F, Lancaster JM, et al. Role of BRCA1 mutation screening in the management of familial ovarian cancer. Am J Obstet Gynecol. 1996;175:738-746.
4. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. JAMA. 1997;277:997-1003.
5. Shepherd JE, Muto MG. Testing for genetic susceptibility to ovarian and breast cancer. Contemporary OB/GYN. 1998;43:88-114.
6. American Cancer Society. Cancer Facts and Figures. Atlanta: American Cancer Society, 1992.
7. Claus EB, Schildkraut JM, Thompson WD, et al. The genetically attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318-2324.
8. Rubin SC, Blackwood MA, Bandera C, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol. 1998;178:670-677.
9. Schneider, KA. Counseling about Cancer: Strategies for Genetic Counselors. Dennisport, MA: Graphic Illusions; 1994.
10. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401-1408.
11. Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet. 1996;14:188-190.
12. Roa BB, Boyd AA, Volcik K, et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14:185-187.
13. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;66:820-823.
14. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994; 265:2088-2090.
15. Couch FJ, Farid LM, DeShano ML, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996;13:123-125.
16. Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997;336:1409-1415.
17. Biesecker B, Boehnke M, Calzone K, et al. Genetic counseling for families with inherited cancer susceptibility to breast and ovarian cancer. JAMA. 1993;269:1970-1974.
18. Hoskins KF, Stopfer JE, Calzone KA, et al. Assessment and counseling for women with a family history of breast cancer: A guide for clinicians. JAMA. 1995;273:577-585.
19. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol. 1996;14:1730-1736.
20. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Cancer. 1994;73:643-651.
21. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879-1886.
22. Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations: risk factor analysis and implications for genetic testing. JAMA. 1997;278:1242-1250.
23. National Cancer Institute Breast Cancer Prevention Trial shows major benefit, some risk [Web site news release] Available: http://cancertrials.nci.nih.gov (accessed May 28, 1998).
24. Veronisi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomized women. Lancet. 1998;352:93-97.
25. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;353:98-101.
26. Grann VR, Panageas KS, Whang W, et al. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA-1 positive or BRCA-2 positive patients. J Clin Oncol. 1998;16:979-985.
27. Piver MS, Jishi MF, Tsukada Y, et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian carcinoma: a report of the Gilda Radner Ovarian Cancer Registry. Cancer, 1993;71:2751-2755.
28. Schrag D, Kuntz KM, Garber JE, et al. Decision analysis: effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 and BRCA2 mutations.
29. Lynch HT, Severin MJ, Mooney MJ, et al. Insurance adjudication favoring prophylactic surgery in hereditary breast-ovarian cancer syndrome. Gynecol Oncol. 1995;57:23-26.
30. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med. 1998;339:424-428.
31. Rubin SC. Chemoprevention of hereditary ovarian cancer. N Engl J Med. 1998;339:469-471.
32. Pate v. Threlkel, 661 So2d 278 (Fla 1995).